Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
J Vasc Interv Radiol. 2023 Oct;34(10):1771-1776. doi: 10.1016/j.jvir.2023.06.014. Epub 2023 Jun 16.
To evaluate the safety and survival outcomes of computed tomography-guided microwave ablation (MWA) for medically inoperable Stage I non-small cell lung cancer (NSCLC) in patients aged ≥70 years.
This study was a prospective, single-arm, single-center clinical trial. The MWA clinical trial enrolled patients aged ≥70 years with medically inoperable Stage I NSCLC from January 2021 to October 2021. All patients received biopsy and MWA synchronously with the coaxial technique. The primary endpoints were 1-year overall survival (OS) and progression-free survival (PFS). The secondary endpoint was adverse events.
A total of 103 patients were enrolled. Ninety-seven patients were eligible and analyzed. The median age was 75 years (range, 70-91 years). The median diameter of tumors was 16 mm (range, 6-33 mm). Adenocarcinoma (87.6%) was the most common histologic finding. With a median follow-up of 16.0 months, the 1-year OS and PFS rates were 99.0% and 93.7%, respectively. There were no procedure-related deaths in any patient within 30 days after MWA. Most of the adverse events were minor.
MWA is an effective and safe treatment for patients aged ≥70 years with medically inoperable Stage I NSCLC.
评估 CT 引导下微波消融（MWA）治疗 70 岁及以上不能手术的Ⅰ期非小细胞肺癌（NSCLC）患者的安全性和生存结果。
本研究为前瞻性、单臂、单中心临床试验。MWA 临床试验于 2021 年 1 月至 2021 年 10 月间招募了年龄≥70 岁且不能手术的Ⅰ期 NSCLC 患者。所有患者均采用同轴技术同步接受活检和 MWA。主要终点为 1 年总生存率（OS）和无进展生存率（PFS）。次要终点为不良事件。
共纳入 103 例患者。97 例患者符合条件并纳入分析。中位年龄为 75 岁（范围，70-91 岁）。肿瘤的中位直径为 16mm（范围，6-33mm）。腺癌（87.6%）是最常见的组织学发现。中位随访 16.0 个月，1 年 OS 和 PFS 率分别为 99.0%和 93.7%。MWA 后 30 天内无患者发生与手术相关的死亡。大多数不良事件为轻微。
MWA 是治疗 70 岁及以上不能手术的Ⅰ期 NSCLC 患者的一种有效且安全的治疗方法。
